Therapeutic Response

CD30 + status confers therapeutic sensitivity to Bendamustine in combination with Brentuximab vedotin in patients with Hodgkin Lymphoma.

Statements

Source and description
Brentuximab vedotin and Bendamustine Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with bendamustine for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).